New results suggest that proactive treatment of severe nonproliferative diabetic retinopathy with aflibercept injections may lead to improvement of disease severity.
Study results from the PANORAMA trial also suggest that these injections can prevent nonproliferative diabetic retinopathy (NPDR) disease progression.
A total of 402 participants were enrolled in 87 sites in the United States, Japan and Europe, and randomly assigned to 3 groups. The first group, after 3 monthly doses and one 8-week interval, received aflibercept injection every 16 weeks for the entire study duration of 100 weeks.